SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001012168-99-000018
Filing Date
1999-03-03
Accepted
1999-03-03 00:00:00
Documents
1
Group Members
ANDREW B. FREMDERDAVID I. COHENENRIQUE H. BOILINIFARALLON CAPITAL (CP) INVESTORS, L.P.FARALLON CAPITAL INSTITUTIONAL PARTNERS II, L.P.FARALLON CAPITAL INSTITUTIONAL PARTNERS III, L.P.FARALLON CAPITAL INSTITUTIONAL PARTNERS, L.P.FARALLON CAPITAL MANAGEMENT

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 10 TO SCHEDULE 13D SC 13D/A 98510
  Complete submission text file 0001012168-99-000018.txt   101350
Mailing Address ONE MARITIME PLAZA SUITE 1325 SAN FRANCISCO CA 94111
Business Address ONE MARITIME PLZ STE 1325 SAN FRANCISCO CA 94111 4154212132
FARALLON CAPITAL MANAGEMENT LLC /ADV (Filed by) CIK: 0001012168 (see all company filings)

IRS No.: 943240279 | State of Incorp.: DE | Fiscal Year End: 1231

Mailing Address 2525 DUPONT DRIVE IRVINE CA 92612
Business Address 2525 DUPONT DRIVE IRVINE CA 92612 7142466912
ALLERGAN SPECIALTY THERAPEUTICS INC (Subject) CIK: 0001049711 (see all company filings)

IRS No.: 330779207 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-53925 | Film No.: 99555769
SIC: 2834 Pharmaceutical Preparations